We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the last reported quarter, the company’s earnings per share (EPS) of 17 cents lagged the Zacks Consensus Estimate by a penny. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on one occasion, missed twice and broke even in the other, delivering an earnings surprise of 13.2%, on average.
Let’s check out the factors that have shaped HIMS’ performance prior to this announcement.
Factors to Note Before Hims & Hers Reports
Hims & Hers is expected to benefit in third-quarter 2025 from the continued expansion of its personalized healthcare platform, which has been driving customer engagement and retention. The company’s investments in lab testing and pharmacy infrastructure are enabling deeper customization of treatment plans and faster care delivery, which management expects will increase subscriber lifetime value and conversion of new users into recurring customers. The ongoing rollout of advanced testing capabilities following the acquisition of a blood testing lab also supports HIMS’ entry into hormonal health and preventive care — both key demand drivers expected to strengthen platform stickiness during the quarter.
Additionally, the launch of the men’s hormonal health category, including the branded oral testosterone KYZATREX, introduces a new, high-demand vertical that broadens Hims & Hers’ addressable market and is likely to attract incremental male subscribers in the to-be-reported quarter. Complementing this, the company’s enhanced AI capabilities under its new chief technology officer are expected to streamline fulfillment, automate patient support and improve clinical decision-making — reducing operating friction while enhancing customer experience, which may further bolster user retention and margins through the quarter.
HIMS’ Estimate Picture
For third-quarter 2025, the Zacks Consensus Estimate for revenues is pegged at $583.7 million, implying an improvement of 45.4% from the prior-year quarter’s reported figure.
The consensus estimate for EPS is pegged at 9 cents, indicating an uptick of 50% from the prior-year period’s reported number.
What Our Model Suggests About Hims & Hers
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has higher chances of beating estimates. This is not the case here, as you can see below.
Earnings ESP: HIMS has an Earnings ESP of -12.79%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Over the past three months, Hims & Hers’ shares have lost 28.1%, underperforming Medical Info Systems’ 3.7% growth. HIMS’ shares also underperformed the Zacks Medical sector and the S&P 500’s gain of 10.9% and 9.8%, respectively.
Three Months Price Comparison
Image Source: Zacks Investment Research
Hims & Hers’ peers like Veeva Systems Inc. (VEEV - Free Report) and 10x Genomics, Inc. (TXG - Free Report) have outperformed the company, while Inspire Medical Systems, Inc. (INSP - Free Report) has underperformed the company. VEEV, INSP and TXG’s shares are up 1.6%, down 41.2% and down 4.1%, respectively, in the same time frame.
Hims & Hers’ Key Valuation Metric
From a valuation standpoint, HIMS’ forward 12-month price-to-sales (P/S) is 3.9X, a discount to the industry's average of 5.8X.
Image Source: Zacks Investment Research
The company is trading at a discount to its peer, Veeva Systems. However, Hims & Hers is trading at a premium to its other peers, 10x Genomics and Inspire Medical. Veeva Systems P/S currently stands at 14X, while the ratios for 10x Genomics and Inspire Medical stand at 2.7X and 2.3X, respectively.
This suggests that investors may be paying a lower price relative to the company's expected sales growth.
HIMS’ Long-Term Investment Visibility
Hims & Hers’ long-term investment visibility continues to strengthen as the company expands into women’s hormonal health through its new menopause and perimenopause specialty. This launch positions the company to capture a major untapped segment, addressing the health needs of over a million U.S. women entering menopause each year. By combining its scalable digital platform with provider-led, personalized care, Hers is creating a durable growth engine that extends beyond traditional telehealth. The move also reinforces HIMS’ commitment to closing critical gaps in women’s healthcare access — an area with significant societal and economic implications. This specialty, supported by prescription-based and non-prescription offerings, is expected to materially enhance Hers’ subscription base and set the division on track toward $1 billion in annual revenues by 2026, indicating sustained visibility for top-line expansion and diversification.
Hims & Hers’ broader investment roadmap — including its recent AI infrastructure development, global expansion through ZAVA and planned entry into Canada — creates a long-term foundation for scalable, technology-driven care delivery. The integration of advanced data systems and AI-supported provider tools is expected to improve care outcomes, enhance operational efficiency and unlock higher-margin opportunities across specialties.
Our Final Take on Hims & Hers
There is no denying that Hims & Hers sits favorably in terms of core business strength, earnings prowess, robust financial footing and global opportunities. The stock’s strong core growth prospects are a good reason for existing investors to retain shares for potential future gains.
For those exploring to make new additions to their portfolios, the valuation indicates superior performance expectations compared with its industry and sector peers. It is still valued lower than the broader market, which suggests potential room for growth if it can align more closely with overall market performance. However, as there are no chances of beating estimates, it would not be a wise choice to add the stock to one’s portfolio before the earnings. However, if investors are already holding the stock, it would be prudent to hold on to it at present. The favorable Zacks Style Score with a Growth Score of A suggests continued uptrend potential for HIMS.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Can Sustained Product Demand Drive HIMS Stock Before Q3 Earnings?
Key Takeaways
Hims & Hers Health, Inc. (HIMS - Free Report) is scheduled to report third-quarter 2025 results on Nov. 3, after the closing bell.
In the last reported quarter, the company’s earnings per share (EPS) of 17 cents lagged the Zacks Consensus Estimate by a penny. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on one occasion, missed twice and broke even in the other, delivering an earnings surprise of 13.2%, on average.
Let’s check out the factors that have shaped HIMS’ performance prior to this announcement.
Factors to Note Before Hims & Hers Reports
Hims & Hers is expected to benefit in third-quarter 2025 from the continued expansion of its personalized healthcare platform, which has been driving customer engagement and retention. The company’s investments in lab testing and pharmacy infrastructure are enabling deeper customization of treatment plans and faster care delivery, which management expects will increase subscriber lifetime value and conversion of new users into recurring customers. The ongoing rollout of advanced testing capabilities following the acquisition of a blood testing lab also supports HIMS’ entry into hormonal health and preventive care — both key demand drivers expected to strengthen platform stickiness during the quarter.
Additionally, the launch of the men’s hormonal health category, including the branded oral testosterone KYZATREX, introduces a new, high-demand vertical that broadens Hims & Hers’ addressable market and is likely to attract incremental male subscribers in the to-be-reported quarter. Complementing this, the company’s enhanced AI capabilities under its new chief technology officer are expected to streamline fulfillment, automate patient support and improve clinical decision-making — reducing operating friction while enhancing customer experience, which may further bolster user retention and margins through the quarter.
HIMS’ Estimate Picture
For third-quarter 2025, the Zacks Consensus Estimate for revenues is pegged at $583.7 million, implying an improvement of 45.4% from the prior-year quarter’s reported figure.
The consensus estimate for EPS is pegged at 9 cents, indicating an uptick of 50% from the prior-year period’s reported number.
What Our Model Suggests About Hims & Hers
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has higher chances of beating estimates. This is not the case here, as you can see below.
Earnings ESP: HIMS has an Earnings ESP of -12.79%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Hims & Hers Health, Inc. Price and EPS Surprise
Hims & Hers Health, Inc. price-eps-surprise | Hims & Hers Health, Inc. Quote
HIMS’ Share Price Performance
Over the past three months, Hims & Hers’ shares have lost 28.1%, underperforming Medical Info Systems’ 3.7% growth. HIMS’ shares also underperformed the Zacks Medical sector and the S&P 500’s gain of 10.9% and 9.8%, respectively.
Three Months Price Comparison
Image Source: Zacks Investment Research
Hims & Hers’ peers like Veeva Systems Inc. (VEEV - Free Report) and 10x Genomics, Inc. (TXG - Free Report) have outperformed the company, while Inspire Medical Systems, Inc. (INSP - Free Report) has underperformed the company. VEEV, INSP and TXG’s shares are up 1.6%, down 41.2% and down 4.1%, respectively, in the same time frame.
Hims & Hers’ Key Valuation Metric
From a valuation standpoint, HIMS’ forward 12-month price-to-sales (P/S) is 3.9X, a discount to the industry's average of 5.8X.
Image Source: Zacks Investment Research
The company is trading at a discount to its peer, Veeva Systems. However, Hims & Hers is trading at a premium to its other peers, 10x Genomics and Inspire Medical. Veeva Systems P/S currently stands at 14X, while the ratios for 10x Genomics and Inspire Medical stand at 2.7X and 2.3X, respectively.
This suggests that investors may be paying a lower price relative to the company's expected sales growth.
HIMS’ Long-Term Investment Visibility
Hims & Hers’ long-term investment visibility continues to strengthen as the company expands into women’s hormonal health through its new menopause and perimenopause specialty. This launch positions the company to capture a major untapped segment, addressing the health needs of over a million U.S. women entering menopause each year. By combining its scalable digital platform with provider-led, personalized care, Hers is creating a durable growth engine that extends beyond traditional telehealth. The move also reinforces HIMS’ commitment to closing critical gaps in women’s healthcare access — an area with significant societal and economic implications. This specialty, supported by prescription-based and non-prescription offerings, is expected to materially enhance Hers’ subscription base and set the division on track toward $1 billion in annual revenues by 2026, indicating sustained visibility for top-line expansion and diversification.
Hims & Hers’ broader investment roadmap — including its recent AI infrastructure development, global expansion through ZAVA and planned entry into Canada — creates a long-term foundation for scalable, technology-driven care delivery. The integration of advanced data systems and AI-supported provider tools is expected to improve care outcomes, enhance operational efficiency and unlock higher-margin opportunities across specialties.
Our Final Take on Hims & Hers
There is no denying that Hims & Hers sits favorably in terms of core business strength, earnings prowess, robust financial footing and global opportunities. The stock’s strong core growth prospects are a good reason for existing investors to retain shares for potential future gains.
For those exploring to make new additions to their portfolios, the valuation indicates superior performance expectations compared with its industry and sector peers. It is still valued lower than the broader market, which suggests potential room for growth if it can align more closely with overall market performance. However, as there are no chances of beating estimates, it would not be a wise choice to add the stock to one’s portfolio before the earnings. However, if investors are already holding the stock, it would be prudent to hold on to it at present. The favorable Zacks Style Score with a Growth Score of A suggests continued uptrend potential for HIMS.